Full-Time

Director of Corporate Affairs Strategy

Analytics & Insights

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$169k - $229k/yr

+ Annual bonus + Discretionary equity awards + Employee Stock Purchase Plan

Remote in USA

Remote

Remote within the United States, with approximately 10% travel.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Power BI
Forecasting
Tableau
Data Analysis

Get referred to BeOne

See people who can refer or advise you

Requirements
  • At least 10 years of Corporate Affairs, Communications, Public Affairs, Patient Advocacy, or related experience within the biopharmaceutical, biotechnology, or life sciences sector, including experience supporting global or multi-regional organizations.
  • Experience leading enterprise transformation initiatives, including applying artificial intelligence, analytics, and emerging technologies to improve organizational effectiveness, decision-making, and business outcomes.
  • Ability to evaluate emerging artificial intelligence tools and translate them into scalable capabilities, processes, and ways of working across Corporate Affairs teams.
  • A proven track record driving adoption of new technologies through governance, change management, stakeholder engagement, and cross-functional partnership.
  • Experience designing and leading enterprise measurement frameworks, operating models, strategic planning processes, or organizational transformation initiatives.
  • Strong understanding of the external stakeholder, policy, regulatory, and reputational landscape shaping global biopharmaceutical companies.
  • A proven ability to influence senior executives, build alignment across highly matrixed organizations, and drive execution through influence rather than direct authority.
  • Experience presenting to executive leadership teams and contributing to Board-level reporting and strategic discussions.
  • Experience managing operational and financial processes, including annual planning, forecasting, governance, resource allocation, and budget oversight.
  • A Bachelor's Degree.
Responsibilities
  • Partner with the Senior Director to lead the annual Corporate Affairs strategic planning process, including AOP and LRP, ensuring alignment between enterprise goals, functional strategies, and regional plans.
  • Manage and scale the Corporate Affairs Impact Intelligence framework across regions and functions.
  • Coordinate the integration of Corporate Affairs goals and deliverables into enterprise-wide initiatives and cross-functional planning cycles.
  • Manage key milestones and governance touchpoints to support timely decision-making and visibility across leadership teams.
  • Lead execution of the Corporate Affairs artificial intelligence roadmap by translating strategic priorities into implementation plans, operating models, governance processes, and measurable business outcomes across the global function.
  • Lead the Corporate Affairs AI Task Force, driving cross-functional alignment, prioritization, and execution of initiatives that advance the function from workflow standardization to connected intelligence and AI-enabled decision support.
  • Own the standardization and scaling of AI-enabled workflows, tools, prompts, and best practices across Corporate Affairs to improve efficiency, consistency, quality, and global adoption.
  • Establish and oversee artificial intelligence measurement, governance, and performance frameworks, including adoption metrics, compliance standards, business impact assessment, and continuous improvement processes.
  • Build the foundation for predictive and influence-based Corporate Affairs capabilities by integrating data, workflows, measurement systems, and feedback loops to enable automated insights, scenario planning, and proactive decision-making.
  • Translate complex qualitative and quantitative data into actionable insights that inform strategy and elevate performance discussions.
  • Prepare and present insight-driven briefings and reports for Corporate Affairs leadership and senior executives, highlighting trends, risks, and opportunities.
  • Collaborate with regional and functional leads to gather intelligence on stakeholder perceptions, emerging issues, and communication effectiveness.
  • Help define and evolve key performance indicators and success measures linking Corporate Affairs activity to business impact.
  • Support the design and delivery of global Corporate Affairs performance reporting, connecting results and insights to strategic narratives.
  • Establish periodic business reviews and leadership updates that demonstrate the impact of Corporate Affairs.
  • Manage the communications and performance operational workstream of key partners in the LMIC patient access program on behalf of BeOne Medicines.
  • Work with Corporate Affairs teams to embed data-driven storytelling into thought leadership and reputation management efforts.
  • Operationalize strategic initiatives, including process improvements, new capability builds, and change adoption across regions.
  • Serve as a key connector across regions and workstreams, fostering collaboration, knowledge sharing, and consistency.
Desired Qualifications
  • A strategic mindset with operational execution excellence.
  • Comfort with ambiguity and change, with a proactive approach to driving improvement.
  • Skill in stakeholder engagement and fostering cross-functional alignment.
  • Passion for data-driven decision-making and continuous improvement.
  • Familiarity with digital analytics tools, including visualization platforms such as Power BI and Tableau, and AI-enabled insights.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.